INS and Hypoglycemia: Our results indicate that velagliflozin, whether used in combination with insulin or as monotherapy, significantly improves glycemic control as reflected by reductions in MG, increases in TIR%, and decreases in TAR%, without increasing TBR% or inducing clinical hypoglycemia.